Phenotypic detection of β-lactamase-mediated resistance to oxyimino-cephalosporins in Enterobacteriaceae: Evaluation of the Mastascan Elite Expert System

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 2, 2005, Pages 292-296

  Winstanley, T G ^a   Parsons, H K ^a   Horstkotte, M A ^b   Sobottka, I ^b   Sturenburg E ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AmpC; CTX M; ESBLs; Expert system; Interpretative reading; K1

Indexed keywords

AGAR; AMPICILLIN; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOMATION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; COMPUTER ANALYSIS; CONTROLLED STUDY; ENTEROBACTERIACEAE; GENOTYPE; NONHUMAN; PHENOTYPE;

BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TESTS; PHENOTYPE;

EID: 23844445916     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki203     Document Type: Article

References (22)

1. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
2. Courvalin P. Interpretive reading of antimicrobial susceptibility tests. Clin Microbiol Infect 1996; 2 Suppl 1: S26-34.
3. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 2001; 47 Suppl 1: 87-102.
4. Stürenburg E, Sobottka I, Feucht HH et al. Comparison of BD Phoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum β-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. Diagn Microbiol Infect Dis 2003; 45: 29-34.
5. Stürenburg E, Sobottka I, Noor D et al. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum β-lactamases in an Enterobacteriaceae isolate collection. J Antimicrob Chemother 2004; 54: 134-8
6. Andrews JM. BSAC standardized disc susceptibility testing method (version 4). J Antimicrob Chemother 2005; 56: Doi:10.1093/ jac/dki124.
7. Faiers M, George R, Jolly J et al. Multipoint Methods in the Clinical Laboratory: A Handbook. London: Public Health Laboratory Service, 1991.
8. Pease AA. Biochemical identification of the Enterobacteriaceae using a multipoint inoculation system. Med Lab Sci 1983; 40: 349-53.
9. Pease AA, Wheat PF, Harris DM. Antimicrobial susceptibility testing and biochemical identification using multipoint inoculation: 5 years' experience. Med Lab Sci 1988; 15: 28-33.
10. Livermore DM. β-Lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998; 41 Suppl D: 25-41.
11. Jehl F, Chomarat M, Weber M et al. Resistance phenotypes of aerobic Gram-negative bacteria to major antibiotics. In: Livermore DM, ed. From Antibiogram to Prescription, 2nd edition. France: Éditions bioMérieux, 2004.
12. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-43.
13. Paterson DL, Ko W-C, von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12
14. Queenan AM, Foleno B, Gownley C et al. Effects of inoculum and β-lactamase activity in AmpC and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004; 42: 269-75.
15. Thomson KS. Controversies about extended-spectrum and AmpC β-lactamases. Emerg Infect Dis 2001; 7: 333-6.
16. Stürenburg E, Sobottka I, Noor D et al. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum β-lactamases in an Enterobacteriaceae isolate collection. J Antimicrob Chemother 2004; 54: 134-8.
17. Bonomo RA, Rice LB. Inhibitor resistant class A β-lactamases. Front Biosci 1999; 4: 34-41.
18. Martinez-Martinez L, Pascual A, Hernandez-Alles S et al. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999; 43: 1669-73.
19. Livermore DM, Struelens M, Amorim J et al. Multicentre evaluation of the VITEK2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. J Antimicrob Chemother 2002; 49: 289-300.
20. Sanders CC, Peyret M, Moland ES et al. Ability of the VITEK 2 advanced expert system to identify β-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 2000; 38: 570-4.
21. Stürenburg E, Sobottka I, Feucht, H-H et al. Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum β-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. Diagn Microbiol Infect Dis 2003; 45: 29-34.
22. St-dsurenburg E, Lang M, Horstkotte MA et al. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum β-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria. J Antimicrob Chemother 2004; 54: 870-875.